The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Dan Veljovich
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Adaptive Biotechnologies; Amgen; AstraZeneca; BioNTech SE; Bristol-Myers Squibb/Roche; Cardinal Health; crispr therapeutics; CVS Health; Doximity; Elevance Health; Gilead Sciences; GlaxoSmithKline; haleon; InVitae; Johnson & Johnson; Medtronic; Merck; Moderna Therapeutics; Pfizer; Seagen; SPDR S and P Biotech ETF; Teladoc; United Health Group; Zimmer BioMet
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca
 
Michael Rothe
No Relationships to Disclose
 
Pam Mangat
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
No Relationships to Disclose
 
Hussein Ali-Ahmad
No Relationships to Disclose
 
R. Naumann
Stock and Other Ownership Interests - Amgen
Honoraria - Johnson & Johnson/MedTech
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Suibb; Eisai; EMD Serono; Genelux; Genmab/Seattle Genetics; GlaxoSmithKline/Tesaro; GOG Partners; Immunogen; Incyclix Bio; Laekna Therapeutics; Merck Sharp & Dohme; Nimbus Therapeutics; Seagen; Sutro Biopharma; Virtual Incision
Speakers' Bureau - Seagen
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Gynecologic Oncology Group (Inst); Mersana (Inst); OncoMed (Inst); Sutro Biopharma (Inst)
 
Jean Siedel
No Relationships to Disclose
 
John Chan
Honoraria - Abbvie; AstraZeneca; Eisai; Genmab/Seagen; GlaxoSmithKline/Tesaro; Immunogen; Merck; Myriad Genetics; Pfizer
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Daiichi Sankyo; Eisai; Ethicon; Immunogen; Mersana; moon surgical; Myriad Genetics; Pfizer; Roche/Genentech; Seagen; Tesaro/GSK
Speakers' Bureau - AstraZeneca; Genmab/Seagen; GlaxoSmithKline/Tesaro; Immunogen; Myriad Genetics
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Eisai; Ethicon; Genmab/Seagen; GlaxoSmithKline; Merck; Myriad Genetics; Pfizer
 
Andrew Gregory
No Relationships to Disclose
 
Evan Pisick
No Relationships to Disclose
 
Bamidele Adesunloye
Consulting or Advisory Role - Astellas Pharma; Eisai; Exelixis
 
Rebecca Arend
Employment - Signatera (I)
Consulting or Advisory Role - Caris Life Sciences; GlaxoSmithKline; KIYATEC; Leap Therapeutics; Merck; Seagan; Sutro Biopharma; VBL Therapeutics
Research Funding - Champions Oncology; Exelixis; GlaxoSmithKline; Immunogen; Merck
Travel, Accommodations, Expenses - Caris Life Sciences; GlaxoSmithKline; VBL Therapeutics
 
Maria Bell
No Relationships to Disclose
 
Marina Frimer
Research Funding - GlaxoSmithKline
 
Bernard Tawfik
Other Relationship - Ipsen
 
Ramya Thota
No Relationships to Disclose
 
Apostolia Tsimberidou
Consulting or Advisory Role - Avstera; BioEclipse Therapeutics; BrYet; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Abbvie (Inst); Agenus (Inst); Anaveon (Inst); BrYet; IMMATICS (Inst); Macrogenics (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Tempus (Inst); Tvardi Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Abby Gregory
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
 
Richard Schilsky
Leadership - Clarified Precision Medicine; Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Honoraria - Toray Industries; WUGEN, Inc.
Consulting or Advisory Role - Bryologyx; Cellworks; Flatiron Health; Illumina; Veracyte; Zephyr AI
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); Taiho Oncology (Inst)